Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-750-4700
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees38
Next Earnings Date6/11/2019 (Estimated)
OptionableNot Optionable
Synthorx (NASDAQ:THOR) Frequently Asked Questions
What is Synthorx's stock symbol?
Synthorx trades on the NASDAQ under the ticker symbol "THOR."
How were Synthorx's earnings last quarter?
Synthorx Inc (NASDAQ:THOR) released its earnings results on Tuesday, March, 12th. The medical instruments supplier reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.77. View Synthorx's Earnings History.
When is Synthorx's next earnings date?
What price target have analysts set for THOR?
4 equities research analysts have issued twelve-month price objectives for Synthorx's stock. Their predictions range from $21.00 to $30.00. On average, they expect Synthorx's share price to reach $25.50 in the next twelve months. This suggests a possible upside of 50.7% from the stock's current price. View Analyst Price Targets for Synthorx.
What is the consensus analysts' recommendation for Synthorx?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthorx in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synthorx.
Has Synthorx been receiving favorable news coverage?
Media coverage about THOR stock has been trending somewhat positive on Monday, according to InfoTrie. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Synthorx earned a news sentiment score of 1.2 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
Are investors shorting Synthorx?
Synthorx saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 1,075,317 shares, an increase of 76.5% from the March 15th total of 609,337 shares. Based on an average daily trading volume, of 100,444 shares, the days-to-cover ratio is currently 10.7 days. Currently, 5.0% of the company's stock are short sold. View Synthorx's Current Options Chain.
Who are some of Synthorx's key competitors?
Some companies that are related to Synthorx include PTC Therapeutics (PTCT), The Medicines (MDCO), Uniqure (QURE), AnaptysBio (ANAB), Endocyte (ECYT), Myokardia (MYOK), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Xencor (XNCR), Ironwood Pharmaceuticals (IRWD), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Enanta Pharmaceuticals (ENTA) and Madrigal Pharmaceuticals (MDGL).
What other stocks do shareholders of Synthorx own?
Who are Synthorx's key executives?
Synthorx's management team includes the folowing people:
- Dr. Laura K. Shawver, CEO, Pres & Director (Age 61)
- Mr. Tighe M. Reardon C.F.A., CPA, CPA, Acting Chief Financial Officer (Age 43)
- Dr. Marcos Milla Ph.D., Chief Scientific Officer (Age 56)
- Dr. Floyd E. Romesberg, Scientific Founder & Director (Age 53)
- Dr. Christian V. Kuhlen, Gen. Counsel (Age 46)
When did Synthorx IPO?
(THOR) raised $100 million in an IPO on Friday, December 7th 2018. The company issued 9,100,000 shares at a price of $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.
When does Synthorx's lock-up period expire?
Synthorx's lock-up period expires on Wednesday, June 5th. Synthorx had issued 11,912,727 shares in its initial public offering on December 7th. The total size of the offering was $131,039,997 based on an initial share price of $11.00. After the end of Synthorx's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Who are Synthorx's major shareholders?
Synthorx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Strs Ohio (0.01%). Company insiders that own Synthorx stock include Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Tighe Reardon. View Institutional Ownership Trends for Synthorx.
Which institutional investors are buying Synthorx stock?
THOR stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Synthorx stock in the last two years include Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Tighe Reardon. View Insider Buying and Selling for Synthorx.
How do I buy shares of Synthorx?
Shares of THOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synthorx's stock price today?
One share of THOR stock can currently be purchased for approximately $16.92.
How big of a company is Synthorx?
Synthorx has a market capitalization of $543.81 million. The medical instruments supplier earns $-56,610,000.00 in net income (profit) each year or ($6.59) on an earnings per share basis. Synthorx employs 38 workers across the globe.
What is Synthorx's official website?
How can I contact Synthorx?
Synthorx's mailing address is 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037. The medical instruments supplier can be reached via phone at 858-750-4700 or via email at [email protected]
MarketBeat Community Rating for Synthorx (NASDAQ THOR)
MarketBeat's community ratings are surveys of what our community members think about Synthorx and other stocks. Vote "Outperform" if you believe THOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe THOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
